Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for January 15, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The company will participate in a presentation and one-on-one investor meetings, and a webcast will be available.
Positive
- None.
Negative
- None.
News Market Reaction – CRBP
On the day this news was published, CRBP declined 0.51%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: BMEA +6.35%, KALA +10.63% versus PYXS -2.54%, EQ -2.55%, FATE -0.59%, suggesting stock-specific trading rather than a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Clinical data update | Positive | -5.7% | Phase 1a CRB-913 obesity data with early weight-loss signal and safety profile. |
| Dec 10 | Data timing update | Neutral | +1.6% | Announcement of upcoming Phase 1a CRB-913 data release and webcast details. |
| Nov 12 | Earnings and update | Positive | +7.4% | Q3 2025 results, CRB-701 efficacy data, financing update and runway into 2028. |
| Nov 06 | Investor conferences | Neutral | -4.2% | Schedule of multiple late-2025 investor conferences with webcasts and meetings. |
| Oct 31 | Equity offering | Negative | -26.1% | Dilutive public equity and pre-funded warrant offering of about $75M gross. |
Stock reactions often aligned with financing and earnings updates, while the positive Phase 1a obesity data on Dec 11, 2025 saw a negative price move, indicating occasional sell-offs on favorable clinical news.
Over the last few months, Corbus combined clinical and financing milestones. A late Oct 2025 public offering led to a -26.09% move, followed by participation in multiple conferences. Q3 2025 results on Nov 12 highlighted strong CRB-701 efficacy data and a cash runway into 2028, with shares up 7.39%. The Phase 1a CRB-913 obesity readout on Dec 11 showed early weight loss signals but the stock fell 5.65%. Today’s J.P. Morgan conference appearance fits the ongoing investor-outreach pattern.
Market Pulse Summary
This announcement highlights Corbus’s participation in the 2026 J.P. Morgan Healthcare Conference, with a scheduled presentation on January 15, 2026. It continues a pattern of active investor outreach following recent financings, clinical readouts for CRB-913, and encouraging CRB-701 data. Investors may watch for any new strategic or clinical updates shared at the meeting, especially around obesity and oncology programs and capital deployment plans.
AI-generated analysis. Not financial advice.
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.
44th Annual J.P. Morgan Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: January 15, 2026
Presentation Time 8:15 a.m. PST/11:15am EST
Webcast Link: Click Here
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
FAQ
When will Corbus Pharmaceuticals (CRBP) present at the J.P. Morgan Healthcare Conference?
Who from Corbus (CRBP) will present at the 2026 J.P. Morgan Healthcare Conference?
How can investors watch Corbus Pharmaceuticals (CRBP) presentation on January 15, 2026?
Will Corbus (CRBP) hold investor meetings at the J.P. Morgan Healthcare Conference?
What topics will Corbus (CRBP) cover in the January 15, 2026 presentation?
Where and when is the 44th Annual J.P. Morgan Healthcare Conference being held?
